6533b85ffe1ef96bd12c1d26

RESEARCH PRODUCT

Review of current and “omics” methods for assessing the toxicity (genotoxicity, teratogenicity and nephrotoxicity) of herbal medicines and mushrooms

Debbie ShawFan QuJean-marie ColetThomas EfferthCaroline StevignyThomas BaudouxJue ZhouMoustapha OuedraogoMoustapha OuedraogoJoëlle NortierOlavi PelkonenPierre DuezKelvin ChanKelvin Chan

subject

Proteomicsmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHerbal MedicineOmicsBiologymedicine.disease_causeKidneyToxicologyNephrotoxicity03 medical and health sciences0302 clinical medicineTeratogenicityDrug DiscoverymedicineMethodsHumansTechnology PharmaceuticalIntensive care medicineEvaluationNephrotoxicity030304 developmental biologyPharmacology0303 health sciencesPlants Medicinalbusiness.industrySciences bio-médicales et agricolesOmics3. Good healthBiotechnologyTeratogens030220 oncology & carcinogenesisMedicine TraditionalGenotoxicitybusinessAgaricalesTranscriptomeGenotoxicityPredictive methodsMutagensPhytotherapy

description

Ethnopharmacological relevance: The increasing use of traditional herbal medicines around the world requires more scientific evidence for their putative harmlessness. To this end, a plethora of methods exist, more or less satisfying. In this post-genome era, recent reviews are however scarce, not only on the use of new "omics" methods (transcriptomics, proteomics, metabonomics) for genotoxicity, teratogenicity, and nephrotoxicity assessment, but also on conventional ones. Methods: The present work aims (i) to review conventional methods used to assess genotoxicity, teratogenicity and nephrotoxicity of medicinal plants and mushrooms; (ii) to report recent progress in the use of "omics" technologies in this field; (iii) to underline advantages and limitations of promising methods; and lastly (iv) to suggest ways whereby the genotoxicity, teratogenicity, and nephrotoxicity assessment of traditional herbal medicines could be more predictive. Results: Literature and safety reports show that structural alerts, in silico and classical in vitro and in vivo predictive methods are often used. The current trend to develop "omics" technologies to assess genotoxicity, teratogenicity and nephrotoxicity is promising but most often relies on methods that are still not standardized and validated. Conclusion: Hence, it is critical that toxicologists in industry, regulatory agencies and academic institutions develop a consensus, based on rigorous methods, about the reliability and interpretation of endpoints. It will also be important to regulate the integration of conventional methods for toxicity assessments with new "omics" technologies. © 2012 Elsevier Ireland Ltd. All rights reserved.

10.1016/j.jep.2012.01.059http://dx.doi.org/10.1016/j.jep.2012.01.059